Nektar Therapeutics (NASDAQ:NKTR)

83.43
Delayed Data
As of Feb 16
 +1.29 / +1.57%
Today’s Change
12.50
Today|||52-Week Range
99.02
+39.70%
Year-to-Date
3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb
Feb 16 / TheStreet.com - Paid Partner Content
Nektar (NKTR) Surges: Stock Moves 11% Higher
Feb 15 / Zacks.com - Paid Partner Content
Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock (Revised)
Feb 16 / Zacks.com - Paid Partner Content
Nektar Shares Surge on Bristol-Myers Collaboration
Feb 14 / TheStreet.com - Paid Partner Content
Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock
Feb 15 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close82.14
Today’s open81.77
Day’s range81.33 - 84.03
Volume2,343,524
Average volume (3 months)2,568,346
Market cap$13.1B
Data as of 4:00pm ET, 02/16/2018

Growth & Valuation

Earnings growth (last year)-80.33%
Earnings growth (this year)+31.82%
Earnings growth (next 5 years)-7.38%
Revenue growth (last year)-28.32%
P/E ratioNM
Price/Sales10.35
Price/Book145.05

Competitors

 Today’s
change
Today’s
% change
AVXSAveXis Inc+0.44+0.38%
ONCESpark Therapeutics I...-0.49-0.89%
XONIntrexon Corp-0.37-2.72%
JUNOJuno Therapeutics In...-0.35-0.41%
Data as of 4:02pm ET, 02/16/2018

Financials

Next reporting dateFebruary 28, 2018
EPS forecast (this quarter)-$0.34
Annual revenue (last year)$165.4M
Annual profit (last year)-$153.5M
Net profit margin-92.80%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Howard W. Robin
Chief Operating Officer &
Senior Vice President
John Nicholson
Corporate headquarters
San Francisco, California

Forecasts